Acute renal failure associated with colistin treatment in the Intensive Care Unit
Abstract
Introduction: The association of colistin and acute kidney injury has shown different results in several studies since the reintroduction of this drug in the common practice. Methods: A prospective and observational study of patients that received treatment with colistin for at least 48 hours in the Intensive Care Unit (ICU) was performed. Results: 104 patients participated in the study, of which 47 % (49) developed acute kidney injury associated to colistin (AKI-C). These patients were grouped according to the RIFLE classification: patients with Risk (10); patients with Injury (13); patients with kidney Failure (26). 6 patients required hemodialysis. The Charlson’s score and the presence of shock were associated to the development of AKI-C. Neither age, APACHE, basal serum creatinine nor accumulated doses of colestin were associated to the development of AKI-C. The AKI-C was associated to a greater in-hospital mortality (p=0.003). Conclusion: The AKI-C is a frequent condition and its associated to a greater in-hospital mortality. The implementation of nephroprotection strategies in patients that receive colestin and the development of new antibiotics with less toxicity could improve the evolution of these patients.
References
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand. 1965;177:717-28.
Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857-68.
Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7(5):R78-83.
Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5:1.
Santamaría C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis. 2009;41(10):767-9.
Rios FG, Luna CM, Maskin B, Saenz Valiente A, Lloria M, Gando S, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J. 2007;30(2):307-13.
Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724-8.
Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503-5.
Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279-91.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Developmentand validation. J Chronic Dis. 1987;40(5):373-83.
Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008; 109:c182-7.
Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720-6.
